MiNK Therapeutics Q3 2023 EPS $(0.15) Beats $(0.18) Estimate
Portfolio Pulse from totan@benzinga.com
MiNK Therapeutics reported Q3 2023 losses of $(0.15) per share, beating the analyst consensus estimate of $(0.18) by 16.67%. This represents a 21.05% increase over losses from the same period last year.
November 09, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MiNK Therapeutics reported better than expected Q3 2023 losses, which could positively impact the stock in the short term.
MiNK Therapeutics reported a smaller loss than expected for Q3 2023, which is generally seen as positive news by investors. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100